Home Autophagy Autophagy

Autophagy Activators/Inhibitors

Other Autophagy Related Inhibitors

LRRK2 OGA Mitophagy ULK LC3 Beclin ATTECs Cell wall GluCls
Cat.No. Product Name Information Product Use Citations Product Validations
S4430 HCQ (Hydroxychloroquine) Sulfate Hydroxychloroquine (HCQ) Sulfate is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9.
EMBO J, 2025, 10.1038/s44318-025-00581-3
iScience, 2025, 28(4):112054
Int J Mol Sci, 2025, 26(2)588
Verified customer review of HCQ (Hydroxychloroquine) Sulfate
S1396 Resveratrol (trans-Resveratrol) Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
PLoS One, 2026 Mar 16, e0344872
PLoS One, 2026 Mar 16, e0344872
Antioxidants, 2025 Oct 29, 1300
Verified customer review of Resveratrol (trans-Resveratrol)
S1049 Y-27632 Dihydrochloride Y-27632 2HCl is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Nature, 2025, 642(8066):143-153
Cell, 2025, S0092-8674(25)00406-4
Cell, 2025, S0092-8674(25)00807-4
Verified customer review of Y-27632 Dihydrochloride
S1263 CHIR-99021 (Laduviglusib) Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 values of 10 nM and 6.7 nM, respectively. It does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. This compound functions as a Wnt/β-catenin activator and induces autophagy.
The Kaohsiung Journal of Medical Sciences, September 12, 2025, e70103
Journal of the American Heart Association, October 2, 2017, e005295
The American Journal of Sports Medicine, February 24, 2025, 1184-1194
Verified customer review of CHIR-99021 (Laduviglusib)
S1060 AZD2281 (Olaparib) Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.
Cell, 2025, 188(18):5081-5099.e27
Cancer Cell, 2025, 43(8):1530-1548.e9
Cancer Cell, 2025, 43(4):776-796.e14
Verified customer review of AZD2281 (Olaparib)
S8048 ABT-199 (Venetoclax) Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.
Cell, 2025, S0092-8674(25)00689-0
Cell, 2025, S0092-8674(25)01233-4
Signal Transduct Target Ther, 2025, 10(1):161
Verified customer review of ABT-199 (Venetoclax)
S7655 Telaglenastat (CB-839) Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. It induces autophagy and has antitumor activity. Phase 1.
Signal Transduct Target Ther, 2025, 10(1):271
Bone Res, 2025, 13(1):62
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
Verified customer review of Telaglenastat (CB-839)
S1378 Ruxolitinib (INCB18424) Ruxolitinib (INCB18424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. This compound kills tumor cells through toxic mitophagy. It induces autophagy and enhances apoptosis.
Nature, 2025, 10.1038/s41586-025-08938-8
Nat Commun, 2025, 16(1):8409
Nat Commun, 2025, 16(1):492
Verified customer review of Ruxolitinib (INCB18424)
S1039 Rapamycin (Sirolimus) Rapamycin is a specific mTOR inhibitor with IC50 of ~0.1 nM in HEK293 cells. This compound binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. It is an autophagy activator and an immunosuppressant.
Nature, 2025, 10.1038/s41586-025-09018-7
Signal Transduct Target Ther, 2025, 10(1):271
Cell Metab, 2025, S1550-4131(25)00294-3
Verified customer review of Rapamycin (Sirolimus)
S2673 Trametinib (GSK1120212) Trametinib (GSK1120212, JTP-74057) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, and it does not inhibit the kinase activities of c-Raf, B-Raf, ERK1/2. This compound activates autophagy and induces apoptosis.
Cancer Cell, 2025, S1535-6108(25)00271-5
Signal Transduct Target Ther, 2025, 10(1):161
Signal Transduct Target Ther, 2025, 10(1):299
Verified customer review of Trametinib (GSK1120212)

Signaling Pathway Map